Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about leuprolide acetate and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):		Lupron Depot-3 Month
		Lupron Depot-4 Month
		Lupron Depot-Ped
		Lupron Depot
		Lupron
		Viadur
FDA Approved:		Yes

Leuprolide acetate is approved by the Food and Drug Administration (FDA) for palliative treatment of advanced prostate cancer.

Leuprolide acetate is also approved to treat the following non-cancer conditions:

• Endometriosis.
• Anemia caused by uterine fibroids (before surgery to remove them).
• Central precocious puberty (a condition in which children begin puberty too early).

Leuprolide acetate is being studied in the treatment of other conditions and types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Leuprolide Acetate - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials for Leuprolide Acetate - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top